FDA approves GSK's Jideytro for ROS1-positive lung cancer, a week after the Nuvalent acquisition closed
Zidesamtinib produced responses in 44% of 117 patients who had already taken a ROS1 inhibitor, and in 48% of those with measurable brain metastases.